Ordering Semaglutide From Overseas: FDA Import Rules and Customs Holds

FDA's personal importation policy does not make it legal to order semaglutide from an overseas website. FDA says that "in most circumstances" importing drugs for personal use is illegal, and the narrow exceptions it describes are built for serious conditions with no effective US treatment, which does not fit a drug sold in the US as Wegovy and Ozempic. If customs holds your package, the notice you receive starts a short administrative process that usually ends with the shipment refused or destroyed.

What the personal importation policy actually says

FDA's personal importation page opens with the general rule: "In most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use." It adds that a drug approved abroad but not approved in the US is an unapproved new drug and cannot be imported.

The page then describes limited circumstances in which FDA staff may use discretion to allow a personal shipment of a prescription product. In summary, the conditions are:

1. The product is for a serious condition for which effective treatment may not be available in the US.
2. There is no known commercialization or promotion of the product to people living in the US.
3. The product does not represent an unreasonable risk.
4. The person importing it affirms in writing that it is for personal use.
5. The quantity is generally no more than a three-month supply.
6. The person names a US-licensed doctor responsible for treatment, or shows the product continues treatment begun abroad.

FDA's Regulatory Procedures Manual, Chapter 9 (March 2024), which instructs FDA import staff, uses the same framework. It states that allowing some shipments "should not be interpreted as a license to individuals to bring in such shipments." The manual also says commercial and promotional shipments are not covered by these procedures, that products posing a significant health risk should be detained, and that products subject to import alerts generally fall outside them.

Why overseas semaglutide generally fails these conditions

Reading the conditions against a typical online semaglutide order shows the problem. This is a description of how the criteria work, not a prediction about any individual package.

Source: FDA, Personal Importation; FDA Regulatory Procedures Manual, Chapter 9, subchapter 9-2 (March 2024).

The 90-day myth

The most repeated claim online is that a three-month supply is legal to import. FDA's page lists a quantity of generally no more than a three-month supply as one condition among several for a discretionary decision. The manual also uses quantity as a signal of commercial intent, treating a shipment as commercial when it exceeds what one person might use in about three months. A small quantity is necessary for discretion, not sufficient for it.

"Compounded" or "generic" labels don't change the analysis

Overseas sellers sometimes describe products as "compounded" or "generic." In the US, compounding under section 503A means a state-licensed pharmacy preparing a drug for an identified patient on a prescription, under conditions FDA restated for GLP-1s in its April 1, 2026 statement. A product made abroad and mailed to a consumer is not a US compounded drug, whatever its label says. A foreign generic is approved, if at all, by another country's regulator, which FDA's importation page says does not make it importable.

What happens when customs holds a package

International mail arrives at International Mail Facilities, where, according to Chapter 9 of FDA's procedures manual, CBP sets aside suspect parcels and FDA reviews them, often by examining labels and inserts rather than testing. Detained parcels "should be held by CBP until they are either released or refused entry."

When FDA detains a parcel, the procedures call for a Notice of FDA Action to the addressee. The manual includes specimen letters for this purpose, including one specifically for "unapproved drug or device mail importations."

Your options under the regulations

Under 21 CFR 1.94, before refusing admission FDA must give the owner or consignee written or electronic notice and "an opportunity to introduce testimony," orally or in writing, at a time the notice sets. The time can be changed on a timely request with reasonable grounds. For drugs, FDA may combine the refusal notice and a destruction notice into one.

In practice, a recipient can:

1. Respond by the deadline with whatever information they want FDA to consider. Whether that changes the outcome depends on the criteria above.
2. Not respond. The notice period ends and FDA proceeds with its decision, typically refusal.
3. Get legal advice if the notice raises questions about your specific situation. This guide cannot assess individual cases.

Destruction of refused drugs

Federal law at 21 U.S.C. 381(a) lets FDA refuse admission to any article that appears adulterated, misbranded, or an unapproved new drug. It also allows FDA to "destroy, without the opportunity for export, any drug" refused admission if it is valued at $2,500 or less (or a higher amount Treasury sets), after notice and an opportunity to appear and present testimony. For a personal-size order, that means a refused package may be destroyed rather than sent back.

This process concerns the shipment only. Nothing in the FDA rules above addresses what you paid; that is between you and the seller or your card issuer.

Counterfeit and quality risks

FDA's guidance on online pharmacies warns that unsafe sites "often sell unapproved, counterfeit or otherwise unsafe medicines" and use fake storefronts to "make you think their medicines come from countries with high safety standards." It notes such products may contain too much or too little active ingredient, the wrong ingredient, or harmful substances, and that medicines stored without temperature control may not work.

Semaglutide has already been counterfeited inside the regulated US supply. FDA's GLP-1 safety page, updated October 1, 2026, says FDA is aware of counterfeit Ozempic in the US drug supply and that counterfeits "could contain the wrong ingredients." The same page advises against using an injectable that "arrives warm or with insufficient refrigeration." International parcels can spend days in transit and inspection with no temperature record.

Worked example

Suppose someone orders "generic semaglutide pens" from a site that ships worldwide and receives a Notice of FDA Action two weeks later. Apply the conditions. Semaglutide is available in the US, so the "no effective domestic treatment" condition is not met. The site markets to US buyers. The product is a foreign drug not approved here. Even if the quantity is under three months, the other conditions fail. The likely outcome under the rules is refusal and, given the value, possible destruction after the notice period.

Scenario guidance

• You are considering an overseas order. The policy is not designed for this situation, and products that arrive have no verifiable chain of custody. Talk with a US prescriber about approved and lawfully dispensed options first.
• You received a Notice of FDA Action. Read the deadline and instructions carefully. Responding is your right; whether it is worth doing depends on facts this guide cannot evaluate.
• Your package arrived. Do not assume it is what the label says. FDA advises against using injectables that arrive warm, and products from unverified sources may be counterfeit. Discuss it with a clinician before use.
• Cost drove the decision. Some manufacturers sell FDA-approved GLP-1s directly to self-pay patients. For example, LillyDirect lists Foundayo (oral orforglipron) starting at $149 per month for the lowest doses, with conditions and temporary pricing noted on the page. Ask your prescriber which approved options fit your situation.

Questions to ask before you buy any GLP-1 online

1. Does the seller require a valid prescription from a US-licensed prescriber?
2. Is the dispensing pharmacy licensed by a US state board of pharmacy, and can I verify it? FDA says that if an online pharmacy is not listed in its BeSafeRx locator, "don't use that pharmacy."
3. Does it list a physical US address and a licensed pharmacist I can reach?
4. Is the product FDA-approved, or compounded by a US pharmacy? Which one?
5. How is it shipped, and how is temperature controlled and documented?

Where this guide stops

This guide summarizes FDA's published policy and federal import law through October 19, 2026. It does not cover state law, criminal law, controlled substances, or rules for travelers carrying their own medication across the border. It does not evaluate any seller, and it is not a substitute for advice from a lawyer about a specific notice or from a clinician about your treatment.

Compare available care options

If you are looking for a lawful, domestic route to GLP-1 treatment, compare what providers will confirm in writing: the prescriber's license, the dispensing pharmacy and its state licenses, and full cost. A listing is not a recommendation or a prescription; verify credentials and terms yourself.

Affiliate disclosure: this site may earn a commission if you use a listed provider. Compensation does not establish a provider's safety, legality, or value.

Sources

1. FDA: Personal Importation
2. FDA Regulatory Procedures Manual, Chapter 9: Import Operations and Actions, subchapter 9-2 (March 2024)
3. 21 CFR 1.94, Hearing on refusal of admission or destruction (eCFR)
4. 21 U.S.C. 381, Imports and exports
5. FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (April 1, 2026)
6. FDA: How to buy medicines safely from an online pharmacy
7. FDA: FDA's concerns with unapproved GLP-1 drugs used for weight loss (updated October 1, 2026)
8. LillyDirect: Foundayo self-pay pricing (accessed October 2026)

Medical disclaimer: This article is general information, not medical advice, and does not replace a licensed clinician who knows your history. Approvals, labels, coverage and prices change; check the linked sources and talk with your prescriber or pharmacist before making decisions about any medication.